Despite significant technical advances in radiation delivery, conventional whole brain radiation therapy (WBRT) has not materially changed in the past 50 years. We hypothesized that IMRT can selectively spare uninvolved brain and scalp with the goal of reducing acute and late toxicity. MRI/CT simulation image registration was performed. We performed IMRT planning to simultaneously treat the brain tumor(s) on MRI 1 5 mm margin to 37.5 Gy in 15 fractions while limiting the uninvolved brain 1 2 mm margin to 30 Gy in 15 fractions and the mean scalp dose to #18 Gy. Three field IMRT plans were compared to conventional WBRT plans. Symptomatic patients were started on conventional WBRT for 2 to 3 fractions while IMRT planning patients preserved between 25 and 50% hair coverage. At a median follow-up of 6.8 months (range: 5 to 15 months), the median overall survival was 5.4 months. Four patients relapsed within the brain, one within the PTV37.5 and three outside the PTV37.5. Tumor directed, scalp sparing IMRT is feasible, achieves rational dose distributions and preserves partial hair coverage in the majority of patients. Further studies are warranted to determine whether the increased utilization of resources needed for IMRT are appropriate in this setting.
Introduction
Whole brain radiotherapy (WBRT) remains a standard treatment approach for patients with multiple brain metastases. WBRT can achieve rapid palliation of neurological symptoms and although data from randomized controlled trials are lacking, retrospective studies suggest that patients treated supportive care with or without corticosteroids have a median survival of 1 to 2 months compared to 3 to 6 months with the addition of WBRT (1, 2) . Additionally, adjuvant WBRT
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has been shown to improve local control and time to neurocognitive function decline in patients with limited (1 to 4) brain metastases that are treated with surgery or stereotactic radiosurgery (3) (4) (5) . Despite significant technical advances in radiation delivery and increased survival in patients with metastatic disease that demonstrate sensitivity to systemic therapies, conventional WBRT has not materially changed in the past 50 years (6) . Several studies have investigated methods of improving the efficacy of WBRT by increasing radiation dose, hyperfractionated radiation schedules and combining WBRT with drug therapy (7) (8) (9) (10) . To date, these efforts have been unsuccessful and little research has focused on improving the therapeutic ratio of WBRT by reducing its toxicity (11) .
One promising approach to improve local control and survival for patients with 1 to 4 brain metastases is to perform stereotactic radiosurgery (SRS) boost in addition to WBRT (12, 13 ). An emerging strategy to reduce the toxicity of WBRT is to administer surgery or SRS alone for patients with limited brain metastases (5, 14) . Eliminating or delaying WBRT results in a higher intracranial recurrence rate that contributes to neurocognitive decline and is challenging to salvage (3, 15, 16) . However, severe alopecia with near complete hair loss is considered a universal complication of conventional WBRT with the majority of patients reporting significant fatigue (17, 18) . Whole brain radiation increases the risk of neurocognitive decline, particularly among long term survivors (3, 19) . In general, radiation oncologists approach treatment planning by selectively targeting the gross tumor 1 margin for microscopic extension and setup uncertainty to the prescription dose while administering a lower dose to areas of subclinical risk (20) . This strategy is extensively utilized in brain, head and neck, lung, gastrointestinal, breast, gynecologic, hematologic and genitourinary tumors. In many centers, over half of the patients are treated with IMRT to improve dose distributions to increase efficacy and/or reduce toxicity (21) . Despite the critical physiological role played by the uninvolved brain, the reason this paradigm has not been extended to WBRT likely relates to the generally poor prognosis of patients with a median survival of 4 months (22) . However, favorable subgroups of patients with brain metastases with median survivals ranging from 7 to 20 months have been identified, suggesting that reducing late toxicity associated with WBRT is an appropriate therapeutic goal for selected patients (5, 22, 23) .
The concept of intensity modulated radiation therapy (IMRT) to improve the dose distribution of WBRT was first proposed in 2005 (24) . One approach is to selectively spare parts of the brain that are critical for neurocognitive function, such as the hippocampal stem cells in the subgranular zone that is currently being tested in RTOG 0933 that is administering WBRT to a total dose of 30 Gy in 10 fractions while limiting the mean hippocampal avoidance zone dose to ,10 Gy (25) . Although this research approach is promising, the hippocampal avoidance zone may be only one of several regions of the brain are involved with memory processing and retention (26) . A second strategy is to selectively boost areas of gross disease while simultaneously treating the uninvolved brain with standard radiation doses (24) . This strategy is currently being tested in countries with socialized health systems such as the United Kingdom and Canada as a cost-effective alternative to stereotactic radiosurgery boost. For example, a published report from England reported the feasibility of treating gross tumors to 40 Gy in 10 fractions while treating the uninvolved brain to 30 Gy in 10 fractions (27) . A third application of whole brain radiation is selective sparing of the scalp (28) . Preliminary work suggests that IMRT can limit the mean scalp dose to 16 to 18 Gy and these reduced doses may shorten the duration of temporary alopecia and possibly reduce the risk of permanent alopecia (28) (29) (30) . Based on these provocative data, we propose a novel IM-WBRT approach that simultaneously reduces radiation dose to the clinically uninvolved brain to doses currently used for prophylactic cranial irradiation for small cell lung cancer while significantly reducing radiation dose to scalp.
Materials and Methods

Patient Selection and Simulation
The Good Samaritan Hospital Medical Center institutional review board (IRB 13-008) approved this retrospective review. All patients provided written informed consent to receive IM-WBRT. We selected adult patients with biopsy proven solid tumor malignancy presenting with one or more brain metastases with a recursive partitioning index of 1 to 2, including patients treated with craniotomy and stereotactic radiosurgery (22) .
Patients were planned with conventional whole brain RT using opposed laterals with custom multileaf collimation or IMRT. Patients with brain metastases underwent diagnostic MRI of the brain with gadolinium contrast-enhance T1-weigted sequence acquisition on a 1.5 T MRI scanner. Contrastenhanced T1-weighted sequence acquisition with a 1.25 mm axial slice thickness was recommended but was optional. Noncontrast CT simulation of the brain with 1.25 mm slice thickness was performed using a custom thermoplastic mask for cranial immobilization in the supine position. CT simulation and T1-weighted axial MRI scans were autofused using Pinnacle and the accuracy of the fusion was visually confirmed.
Contouring
The clinical target volume (CTV) was defined as the gross target volume (GTV) of all intracranial tumors contoured on T1-weighted MRI axial sequences ( Figure 1 ). For patients who
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underwent surgery or stereotactic radiosurgery, the pretreatment tumors were contoured as clinical target volume (CTV). The brain, brainstem, scalp, eyes and lens were contoured on CT and cross-referenced to the fused MRI. The scalp contour is defined as the skin 1 3 mm depth from the level of the canthi to the vertex. The PTV37.5 was defined as CTV 1 5 mm. To account for setup uncertainty, the PTV30 was defined as brain 1 2 mm while encompassing the PTV37.5.
Treatment Planning and Plan Evaluation
We developed a custom 3-field static IMRT plan using Pinnacle 8.0 using direct machine parameter optimization. IMRT plans were calculated using the adaptive convolution algorithm. Treatment was performed on a Varian Clinac 21 C/D linear accelerator equipped with millennium 120 multileaf collimators using 6 MV photons. The standard field arrangement is right anterior oblique (275°), left anterior oblique (85°) and superior anterior oblique (gantry 30 to 55°; collimator 90°). The field size is set to encompass the whole brain with a 2 cm margin. We used up to 50 segments with a minimum segment area of 6 cm 3 .
Treatment planning criteria included .95% of the PTV37.5 received the prescription dose of 37.5 Gy and 95% of the PTV30 received the prescription dose of 30 Gy. The mean scalp dose was limited to ,18 Gy. The maximum brainstem dose is 37.5 Gy, the maximum dose to the optic tracts is ,37.5 Gy, the maximum eye dose is 7 Gy and the maximum lens dose is 5 Gy. For the C-WBRT group, the PTV37.5 is defined as the entire brain. No attempt will be made to selectively spare the uninvolved brain or scalp. We documented target coverage, conformity index, homogeneity index, V95, mean brain-PTV37.5 and mean scalp doses. Homogeneity index was defined as D max /37.5 Gy for all each plan. Conformality index was defined as the volume receiving 37.5 Gy/volume of the PTV37.5.
Baseline and Follow-up Assessment
The Duke University Severity in Alopecia Tool (SALT) score will be used to objectively quantify hair loss from photographs of the scalp taken before and after treatment (31) . Briefly, S 0 is no hair loss, S 1 is #25% hair loss, S 2 is 25 to 49% hair loss, S 3 is 50 to 74% hair loss, S 4 is 75 to 99% hair loss and S 5 is 100% hair loss. After completion of WBRT, all patients returned for routine history and physical examinations at 4, 12 and 24 weeks after whole brain radiotherapy and every 6 months thereafter. Additionally, patients underwent repeat MRI of the brain at these timepoints to assess response to treatment. All patients were followed until death for disease control and toxicity. Intracranial control is defined as freedom from intracranial progression using RECIST criteria or stable disease with neurological deterioration. Failures were classified as within the PTV37.5 or new metastases outside of the PTV37.5. Date of death was confirmed by using the Social Security Death Index. Patients were censored for intracranial control at time of last clinical follow-up or imaging. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0. to WBRT. Other patients with brain metastases treated in the department were excluded from IMRT due to poor performance status (n 5 4), leptomeningeal spread (n 5 3), treatment with stereotactic radiosurgery alone (n 5 4), ineligibility for IMRT due to insurance or inability to undergo magnetic resonance imaging (MRI) (n 5 3). (Figure 1 and Table II 
Dosimetric Comparison
Statistical Analysis
Statistical analysis was performed using Stata 8. Treatment plan parameters were compared using a paired 2-tailed t-test. We estimated actuarial local control and overall survival using the Kaplan-Meier method.
Results
Patient Population
We treated 17 consecutive patients from 6/12 to 6/13 with IMRT whole brain radiation therapy for 1 or more brain metastases (Table I) . Median age was 64, 59% male, 65% lung primary, 18% recursive partitioning analysis (RPA) class 1, 82% RPA class 2 to 3, 82% multiple brain metastases, 24% received SRS and 24% received surgery prior Toxicity IMRT whole brain radiation was generally well tolerated and all 17 patients received the prescribed dose of 37.5 Gy. There was no grade 3 toxicity. Nine patients reported grade 1 or grade 2 fatigue. Six patients reported symptoms related to corticosteroids, including weight gain, hyperglycemia, thrush and insomnia. Two patients reported skin erythema and one patient reported skin itching. With respect to alopecia, two patients were not assessable because they were unable to return for clinical follow-up due to progressive disease. Of the remaining 15 assessable patients, no patient had complete hair loss. At one month to three months following IM-WBRT, four patients (27%) had ,50% hair loss, six patients (40%) had 50 to 74% hair loss and five patients (33%) had 75 to 99% hair loss (Figure 2) . Among the five patients with 75 to 99% hair loss, two patients had 75 to 99% hair loss prior to IM-WBRT and one patient was receiving chemotherapy at the time of reevaluation. Five patients surviving more than 6 months had no alopecia or late neurocognitive toxicity at last follow-up.
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Overall Survival and Patterns of Failure
With a median follow-up of 6.8 months (range 5 to 15 months), the median overall survival is 5.4 months (Supplemental Figure 1 ). Four patients failed in the brain, one within the PTV 37.5 and three outside the PTV37. of alopecia. Fourth, select subgroups with brain metastases are not appropriate for IM-WBRT, including patients with a poor performance status and leptomeningeal carcinomatosis are associated with a median survival of approximately 2 months (22, 31) . Finally, we made no attempt to selectively spare the hippocampus or other areas of the brain that affect cognitive function in this pilot study. As our understanding of brain function and radiosensitivity of brain subunits continues to improve, selective cognitive sparing IMRT can easily be integrated into the IM-WBRT platform described (25) .
To address these limitations, a randomized trial comparing IM-WBRT vs. conventional WBRT is ongoing for patients with RPA class I and II brain metastases (NCT01890278). In this study, the primary endpoint is short-term (1 to 4 months) alopecia as assessed using the SALT scale (32) . Further, cognitive function assessed by mini-mental status examination and patient-reported quality of life assessed by the EORTC QLQ BN-20 will be compared. Local control and overall survival will also be assessed. We will also compare length of professional time required for image fusion, contouring, treatment planning, quality assurance, treatment delivery and cost between conventional whole brain RT and IM-WBRT. These data will provide more definitive data on the clinical benefit and cost effectiveness of IM-WBRT. Further, the efficacy, toxicity and cost-effectiveness profile of IM-WBRT should be rigorously compared to stereotactic radiosurgery for patients with 4 brain metastases.
Conventional WBRT is generally well tolerated, save for alopecia, fatigue and short-term neurocognitive decline in patients with a short life expectancy (#6 months) (12, 18, 33) . In a recent randomized trial at MD Anderson, WBRT after SRS increased the risk of neurocognitive decline 5 points as assessed by the Hopkins Verbal Learning Test at 4 months after treatment compared to SRS alone (49% vs. 23%, p , 0.05) (14) . In other studies, development of subsequent brain metastases is a significant contributor to cognitive decline (3, 15, 16) . In long term survivors (12 months), irreversible neurocognitive decline has been reported in up to 11% of patients treated with conventional WBRT, although this study utilized daily radiation doses .3 Gy per day that are no longer in common use (19) . The decline in cognitive function assessed by mini mental status examination may take up to 3 years to manifest (3).
In the setting of prophylactic WBRT for small cell and nonsmall cell lung cancer, lower radiation doses of 25 to 30 Gy in 10 to 15 fractions are considered standard treatment (34) (35) (36) .
In a randomized trial of prophylactic cranial irradiation for small cell lung cancer, there was no evidence of improved disease control with 36 Gy vs. 25 Gy (35) . While prophylactic cranial WBRT to 25 to 30 Gy in 10 to 15 fractions has been intracranial failures, including two patients with small cell lung cancer who initially had complete response within the brain, were subsequently diagnosed with widespread intracranial and extracranial progression. The 6-month actuarial intracranial control rate is 70% (Figure 3 ). To date, 2 patients remain free of either intracranial or extracranial progression at 143 and 204 days, respectively.
Discussion
In this manuscript, we describe a novel approach to improving the dose distribution associated with whole brain radiotherapy. Patients treated with IM-WBRT were followed clinically and 27% of assessable patients preserved at least 50% of scalp hair coverage at 1 to 3 months following treatment while the majority of patients preserved at least 25% hair coverage ( Figure 2 ). Although three patients failed outside the PTV37.5, these patients were diagnosed with widespread extracranial metastases at the time of the intracranial recurrence. Thus, there was no evidence of decreased local control or survival resulting from dose deescalation for the uninvolved brain.
There are several important limitations of this feasibility study. First, this study is primarily a dosimetric analysis with limited clinical correlation. Second, extensive quality of life and cognitive function data were not assessed. Third, our preliminary data were obtained using a simple 3-field static IMRT plan and improved dose distributions may be possible using additional fields or volumetric tomotherapy and could further reduce the severity and extent (36, 37) . Recent data suggests a relationship between increasing prophylactic cranial irradiation dose and deficits in verbal memory function (38) . Additionally, there are robust data from randomized trials reproducibly demonstrating a significant reduction in the incidence of subsequent brain metastases in patients with small cell and non-small cell lung cancer receiving prophylactic WBRT (34, 36, 39) . A theoretical disadvantage of limiting WBRT to 30 Gy in 15 fractions is that this dose may be inadequate to prevent relapse in relatively radioresistant tumors. However, as discussed earlier, some investigators are now administering 0 Gy to uninvolved sites by deferring WBRT due to concerns of toxicity (16) .
An overarching question in the field of brain metastases management is defining indication for whole brain radiation (40) . At the minimum, patients with small cell lung cancer requiring prophylactic cranial irradiation and patients with a large number of discrete metastases will require whole brain radiotherapy. Patients with 1 to 3 brain metastases treated with either surgery or stereotactic radiosurgery are potential candidates for adjuvant whole brain radiation, although this remains hotly debated (3) (4) (5) . Finally, there is emerging data on using stereotactic radiosurgery for selected patients with
